Scientific article
OA Policy
English

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Published inAlzheimer's & dementia, vol. 13, no. 3, p. 285-295
Publication date2017
Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

Citation (ISO format)
HERUKKA, Sanna-Kaisa et al. Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. In: Alzheimer’s & dementia, 2017, vol. 13, n° 3, p. 285–295. doi: 10.1016/j.jalz.2016.09.009
Main files (1)
Article (Published version)
Identifiers
Journal ISSN1552-5260
505views
139downloads

Technical informations

Creation08/06/2017 12:30:00
First validation08/06/2017 12:30:00
Update time15/03/2023 01:46:19
Status update15/03/2023 01:46:17
Last indexation31/10/2024 07:09:50
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack